Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer.
The BRCA1 and BRCA2 genes are responsible for a high proportion of familial breast cancer; germline mutations in these genes confer a lifetime risk of about 70% for developing breast cancer. Most of the described deleterious mutations are small deletions or insertions that originate a truncated protein; however, in many cases, they are amino acid changes whose significance is unknown. In these cases, there are some tests that can analyze the meaning of these variants, but most remain unclassified. The BRCA genes are tumor suppressors and it is believed that complete loss of the wild-type allele is a common mechanism of inactivation in tumors from patients carrying a germline deleterious mutation in these genes; if this is true, loss of heterozygosity (LOH) analysis in the tumor sample could help to distinguish if a rare variant is either a deleterious mutation or a common polymorphism. In the present study, we performed LOH analysis at the BRCA loci in 47 tumors from patients who belonged to high-risk breast cancer families and were carriers of any type of alteration in these genes. Our results suggest that (i) loss of the wild-type allele is the most common mechanism of inactivation in tumors from patients who carry a deleterious mutation in any of the genes, (ii) this loss is not common when we analyze familial tumors not associated with mutations in BRCA and (iii) LOH can be used to clarify variants of unknown significance in the BRCA genes.
Osorio
Ana
A
Department of Human Genetics, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain. aosorio@cnio.es
de la Hoya
Miguel
M
Rodríguez-López
Raquel
R
Martínez-Ramírez
Angel
A
Cazorla
Alicia
A
Granizo
Juan José
JJ
Esteller
Manel
M
Rivas
Carmen
C
Caldés
Trinidad
T
Benítez
Javier
J
D000483:Alleles; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics*; D004586:Electrophoresis; D005260:Female; D006579:Heterozygote; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D010051:Ovarian Neoplasms / Q000235:genetics; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D018807:Polymorphism, Single-Stranded Conformational; D012680:Sensitivity and Specificity
D019313:BRCA1 Protein; D024682:BRCA2 Protein